{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:41:27Z","timestamp":1762072887688,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Poly(adenosine diphosphate-ribose) polymerase inhibitors are approved to treat patients harboring a germline breast cancer susceptibility gene 1 or 2 mutation (BRCA1\/2mut) with human epidermal growth factor receptor 2\u2014negative (HER2\u2212) advanced breast cancer (ABC). This study evaluated differences in patient demographics, clinical characteristics, and BRCA1\/2mut testing within the United States (US), European Union 4 (EU4; France, Germany, Italy, and Spain), and Israel in a real-world population of patients with HER2\u2212 ABC. Oncologists provided chart data from eligible patients from October 2019 through March 2020. In the US, EU4, and Israel, 73%, 42%, and 99% of patients were tested for BRCA1\/2mut, respectively. In the US and the EU4, patients who were not tested versus tested for BRCA1\/2mut were more likely to have hormone receptor\u2014positive (HR+)\/HER2\u2212 ABC (US, 94% vs. 74%, p &lt; 0.001; EU4, 96% vs. 78%, p &lt; 0.001), less likely to have a known family history of BRCA1\/2-related cancer (US, 6% vs. 19%, p = 0.002; EU4, 10% vs. 28%, p &lt; 0.001), and were older (US, 68.9 vs. 62.5 years, p &lt; 0.001; EU4, 66.7 vs. 58.0 years, p &lt; 0.001). Among tested patients, genetic counseling was received by 45%, 53%, and 98% with triple-negative breast cancer, and 36%, 36%, and 98% with HR+\/HER2\u2212 ABC in the US, EU4, and Israel, respectively. Efforts should be made to improve BRCA1\/2 testing rates in the US and Europe.<\/jats:p>","DOI":"10.3390\/cancers14215399","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T03:11:21Z","timestamp":1667445081000},"page":"5399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BRCA1\/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel"],"prefix":"10.3390","volume":"14","author":[{"given":"Reshma","family":"Mahtani","sequence":"first","affiliation":[{"name":"Miami Cancer Institute, 8900 Kendall Drive, Miami, FL 33176, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-9661","authenticated-orcid":false,"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[{"name":"Patient and Health Impact, Pfizer Inc., 235 42nd St., New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhakti","family":"Arondekar","sequence":"additional","affiliation":[{"name":"Patient Health and Impact, Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[{"name":"Oncology Franchise, Adelphi Real World, Adelphi Mill, Cheshire, Bollington SK10 5JB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[{"name":"Oncology Franchise, Adelphi Real World, Adelphi Mill, Cheshire, Bollington SK10 5JB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Massey","sequence":"additional","affiliation":[{"name":"Oncology Franchise, Adelphi Real World, Adelphi Mill, Cheshire, Bollington SK10 5JB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Frauenklinik St. Josefs, Salzkotten Husener Stra\u00dfe 81, 33098 Paderborn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12687-011-0042-4","article-title":"Genetic testing for familial\/hereditary breast cancer\u2014Comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany","volume":"2","author":"Gadzicki","year":"2011","journal-title":"J. Community Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer\u2014Association with patient and disease characteristics and effect on prognosis","volume":"39","author":"Fasching","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"V94","DOI":"10.1093\/annonc\/mdx365.047","article-title":"Real-life study of BRCA genetic screening in metastatic breast cancer","volume":"28","author":"Meynard","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1758835919897530","DOI":"10.1177\/1758835919897530","article-title":"How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors","volume":"12","author":"Neviere","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_7","unstructured":"US Food and Drug Administration (2022, January 31). FDA Approves Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer."},{"key":"ref_8","unstructured":"US Food and Drug Administration (2022, January 31). FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","article-title":"Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial","volume":"120","author":"Robson","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: Detailed safety analyses from the phase III EMBRACA trial","volume":"25","author":"Hurvitz","year":"2020","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8753","DOI":"10.1038\/s41598-020-63033-4","article-title":"Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis","volume":"10","author":"Im","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","volume":"22","author":"Ramon","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014A means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_18","unstructured":"European Pharmaceutical Market Research Association (2021, September 01). EphMRA Code of Conduct. Available online: https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf."},{"key":"ref_19","unstructured":"US Department of Health & Human Services (2021, May 26). Summary of the HIPAA Privacy Rule, Available online: https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/laws-regulations\/index.html."},{"key":"ref_20","unstructured":"(2021, September 01). Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.4.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All Rights Reserved. Accessed July 5, 2022. To View the Most Recent and Complete Version of the Guideline, NCCN Makes No Warranties of Any Kind Whatsoever Regarding Their Content, Use or Application and Disclaims any Responsibility for Their Application or Use in any Way. Available online: NCCN.org."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2217\/fon-2021-1387","article-title":"Real-world multi-country study of BRCA1\/2 mutation testing among adult women with HER2-negative advanced breast cancer","volume":"18","author":"Lux","year":"2022","journal-title":"Future Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-011-1711-z","article-title":"Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations","volume":"130","author":"Bayraktar","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clbc.2021.12.007","article-title":"Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1\/2 mutations or mutations in non-BRCA1\/2, DNA damage repair genes","volume":"22","author":"Walsh","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: A position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"ref_25","unstructured":"US National Institutes of Health (2022, April 27). BRCA Gene Mutations: Cancer Risk and Genetic Testing, Available online: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/brca-fact-sheet#r18."},{"key":"ref_26","unstructured":"The Health Policy Partnership (2022, May 23). Genetic Testing for BRCA Mutations: A Policy Paper. Available online: https:\/\/www.healthpolicypartnership.com\/app\/uploads\/Genetic-testing-for-BRCA-mutations-a-policy-paper.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41431-018-0252-x","article-title":"The global state of the genetic counseling profession","volume":"27","author":"Abacan","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014What is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:16Z","timestamp":1760144956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":28,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14215399"],"URL":"https:\/\/doi.org\/10.3390\/cancers14215399","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}